Challenges and Considerations in Metformin Use for ADPKD: A Commentary on Recent Findings.
作者信息
Patil Amol N, Singh Mahendra Pratap, Rawat Pramod, Sah Sanjit, Satapathy Prakasini
机构信息
Department of Pharmacology, PGIMER, Chandigarh, India.
Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
出版信息
Indian J Nephrol. 2025 May-Jun;35(3):443. doi: 10.25259/IJN_513_2024. Epub 2024 Nov 6.
Abstract
摘要
相似文献
1
Challenges and Considerations in Metformin Use for ADPKD: A Commentary on Recent Findings.多囊肾病使用二甲双胍的挑战与考量：对近期研究结果的评论
Indian J Nephrol. 2025 May-Jun;35(3):443. doi: 10.25259/IJN_513_2024. Epub 2024 Nov 6.
2
Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.二甲双胍改善常染色体显性遗传性多囊肾病小鼠模型的相关疾病参数。
Am J Physiol Renal Physiol. 2022 Jan 1;322(1):F27-F41. doi: 10.1152/ajprenal.00298.2021. Epub 2021 Nov 22.
3
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?二甲双胍在常染色体显性多囊肾病中的应用：实验假说还是临床事实？
BMC Nephrol. 2018 Oct 22;19(1):282. doi: 10.1186/s12882-018-1090-3.
4
Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease.常染色体显性多囊肾病和二甲双胍：延缓慢性肾脏病进展的既有认识和新见解。
Med Res Rev. 2022 Jan;42(1):629-640. doi: 10.1002/med.21850. Epub 2021 Jul 30.
5
Metformin Use and Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Nationwide Cohort Study.二甲双胍在常染色体显性多囊肾病中的应用及临床结局：一项全国性队列研究
Biomedicines. 2025 Mar 5;13(3):635. doi: 10.3390/biomedicines13030635.
6
Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.常染色体显性遗传多囊肾病的二甲双胍治疗：一项可行性研究。
Am J Kidney Dis. 2022 Apr;79(4):518-526. doi: 10.1053/j.ajkd.2021.06.026. Epub 2021 Aug 12.
7
Metformin Versus Standard of Care in Patients with Autosomal Dominant Polycystic Kidney Disease - A Randomized Control Trial.二甲双胍与常染色体显性多囊肾病患者的标准治疗对比——一项随机对照试验
Indian J Nephrol. 2025 May-Jun;35(3):410-416. doi: 10.25259/IJN_100_2024. Epub 2024 Aug 29.
8
Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants.TAME-PKD临床试验参与者中纵向尿代谢生物标志物与常染色体显性多囊肾病严重程度及二甲双胍反应的关联
Kidney Int Rep. 2022 Dec 5;8(3):467-477. doi: 10.1016/j.ekir.2022.11.019. eCollection 2023 Mar.
9
Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.血管加压素 V2 受体拮抗剂治疗多囊肾病时氢氯噻嗪和二甲双胍对水通透性和肾脏保护作用的随机交叉试验。
Clin J Am Soc Nephrol. 2022 Apr;17(4):507-517. doi: 10.2215/CJN.11260821. Epub 2022 Mar 21.
10
Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials.饮食干预和二甲双胍对常染色体显性多囊肾病患者管状生物标志物的影响：两项临床试验的事后分析。
BMC Nephrol. 2024 Jun 25;25(1):206. doi: 10.1186/s12882-024-03643-6.
本文引用的文献
1
Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study.基于肾功能状态的二甲双胍对 2 型糖尿病患者心血管和肾脏结局的影响：一项多中心、回顾性队列研究。
Sci Rep. 2024 Jan 24;14(1):2081. doi: 10.1038/s41598-024-52078-4.
2
Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.SGLT2 抑制剂在 2 型糖尿病中的剂量依赖性肾保护疗效：系统评价和网络荟萃分析。
Acta Diabetol. 2023 Oct;60(10):1311-1331. doi: 10.1007/s00592-023-02126-8. Epub 2023 Jun 15.
3
Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.常染色体显性遗传多囊肾病的二甲双胍治疗：一项可行性研究。
Am J Kidney Dis. 2022 Apr;79(4):518-526. doi: 10.1053/j.ajkd.2021.06.026. Epub 2021 Aug 12.
4
Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2α-VEGF-A pathway.二甲双胍通过激活 HIF-2α-VEGF-A 通路减少自发性高血压大鼠的蛋白尿。
Eur J Pharmacol. 2021 Jan 15;891:173731. doi: 10.1016/j.ejphar.2020.173731. Epub 2020 Nov 18.
5
A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?二甲双胍-丁酸盐协同作用通过改变肠道微生物群来控制各种病理状况的故事：一种神奇药物的诞生？
Pharmacol Res. 2017 Mar;117:103-128. doi: 10.1016/j.phrs.2016.12.003. Epub 2016 Dec 8.
Zotero 插件